Fukuda Minoru

フクダミノル | Fukuda Minoru

Affiliation and department：
Papers (25)：

Takemoto S, Fukuda Mi, Yamaguchi H, Ikeda T, Akagi K, Tomono H, Umeyama Y, Dotsu Y, Taniguchi H, Gyotoku H, et al. Phase II study of ramucirumab and docetaxel for previously treated non-small cell lung cancer patients with malignant pleural effusion: protocol of PLEURAM study. Thorac Cancer. 2020
Ohue Y, Kurose K, Karasaki T, Isobe M, Yamaoka T, Futami J, Irei I, Masuda T, Fukuda Ma, Kinoshita A, et al. Serum antibody against NY-ESO-1 and XAGE1 antigens potentially predicts clinical responses to Anti-PD-1 therapy in non-small cell lung cancer. J Thorac Oncol. 2019. 14. 12. 2071-2083
Midori Shimada, Hiroyuki Yamaguchi, Minoru Fukuda, Hiromi Tomono, Noritaka Honda, Yosuke Dotsu, Hirokazu Taniguchi, Hiroshi Gyotoku, Hiroaki Senju, Shinnosuke Takemoto, et al. Dose escalation study of amrubicin and cisplatin with concurrent thoracic radiotherapy for limited-disease small cell lung cancer. Cancer chemotherapy and pharmacology. 2019. 84. 5. 1059-1064
Hirokazu Taniguchi, Hiroyuki Yamaguchi, Yosuke Dotsu, Midori Shimada, Hiroshi Gyotoku, Hiroaki Senju, Shinnosuke Takemoto, Takeshi Kitazaki, Masaaki Fukuda, Daiki Ogawara, et al. Phase II study of nedaplatin and amrubicin as first-line treatment for advanced squamous cell lung cancer. Thoracic cancer. 2019. 10. 9. 1764-1769
Nakao A, Hiranuma O, Uchino J, Sakaguchi C, Kita T, Hiraoka N, Ishizuka T, Kubota Y, Kawasaki M, Goto Y, et al. Osimertinib in elderly patients with epidermal growth factor receptor T790M-positive non-small-cell lung cancer who progressed during prior treatment: a phase II trial. The Oncologist. 2019. 24. 1-7

ｍore...

※ Researcher’s information displayed in J-GLOBAL is based on the information registered in researchmap. For details, see here.

Return to Previous Page